Eur Rev Med Pharmacol Sci 2021; 25 (18): 5690-5700

DOI: 10.26355/eurrev_202109_26788

Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience

L. Monzo, C. Gaudio, F. Cicogna, C. Tota, V. Petronilli, S. Mennuni, E. De Ruvo, L. Calò

Department of Cardiology, Policlinico Casilino, Rome, Italy. luca.monzo@uniroma1.it


OBJECTIVE: Current guidelines recommend an implantable cardiac defibrillator (ICD) in patients with symptomatic heart failure and reduced ejection fraction (HFrEF; left ventricular ejection fraction [LVEF] ≤35%) despite ≥3 months of optimal medical therapy. Recent observations demonstrated that sacubitril/valsartan induces beneficial reverse cardiac remodeling in eligible HFrEF patients. Given the pivotal role of LVEF in the selection of ICD candidates, we sought to assess the impact of sacubitril/valsartan on ICD eligibility and its predictors in HFrEF patients.

PATIENTS AND METHODS: We retrospectively evaluated 48 chronic HFrEF patients receiving sacubitril/valsartan and previously implanted with an ICD in primary prevention. We assumed that ICD was no longer necessary if LVEF improved >35% (or >30% if asymptomatics) at follow-up.

RESULTS: Over a median follow-up of 11 months, sacubitril/valsartan induced a significant drop in LV end-systolic volume (-16.7 ml/m2, p=0.023) and diameter (-6.8 mm, p=0.022), resulting in a significant increase in LVEF (+3.9%, p<0.001). As a consequence, 40% of previously implanted patients resulted no more eligible for ICD at follow-up. NYHA class improved in 50% of the population. A dose-dependent effect was noted, with higher doses associated to more reverse remodeling. Among patients deemed no more eligible for ICD, lower NYHA class (odds ratio (OR) 3.73 [95% CI 1.05; 13.24], p=0.041), better LVEF (OR 1.23 [95% CI 1.01; 1.48], p=0.032) and the treatment with the intermediate or high dose of sacubitril/valsartan (OR 5.60 [1.15; 27.1], p=0.032) were the most important predictors of status change.

CONCLUSIONS: In symptomatic HFrEF patients, sacubitril/valsartan induced beneficial cardiac reverse remodeling and improved NYHA class. These effects resulted in a significant reduction of patients deemed eligible for ICD in primary prevention.

Free PDF Download

To cite this article

L. Monzo, C. Gaudio, F. Cicogna, C. Tota, V. Petronilli, S. Mennuni, E. De Ruvo, L. Calò
Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 18
Pages: 5690-5700
DOI: 10.26355/eurrev_202109_26788